1228392-59-3

Basic information

• Product Name: N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester
• Synonyms: N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester
• CAS NO: 1228392-59-3
• Molecular Weight: 417.257
• Mol File: 1228392-59-3.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester(1228392-59-3)
• EPA Substance Registry System: N-(4-bromo-2-nitrophenyl)-N-tert-butoxycarbonylcarbamic acid tert-butyl ester(1228392-59-3)

Safety Data

• Hazardous Substances Data: 1228392-59-3(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 875-51-4 4-Bromo-2-nitroaniline 

Downstream Products

• 327046-79-7 tert-butyl (4-bromo-2-nitrophenyl)carbamate 

Relevant articles and documents

Fused tricyclic derivative as FGFR4 inhibitor

The present invention provides a fused tricyclic derivative that is the selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a pharmaceutical composition containing the compound, a method of making the compound and a method of treating cell proliferative diseases, such as cancer, using the compounds of the invention.

PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF IN MEDICINE

The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.

Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode